Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?

Stavros V. Konstantinides

doi:10.1160/th15-10-0832

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2016; 115(02): 233-235
DOI: 10.1160/th15-10-0832

Invited Editorial Focus

Schattauer GmbH

Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?

Authors

Stavros V. Konstantinides

¹Centre for Thrombosis and Haemostasis, University Medical Centre of the Johannes Gutenberg University, Mainz, Germany

²Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece

Abstract

Volltext

Referenzen

References
1 Konstantinides SV, Torbicki A, Agnelli G. et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; 35: 3033-3073.
2 Lilienfeld DE, Godbold JH, Burke GL. et al. Hospi-talization and case fatality for pulmonary embolism in the twin cities: 1979-1984. Am Heart J 1990; 120: 392-395.
3 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPEr). Lancet 1999; 353: 1386-1389.
4 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
5 Kearon C, Akl EA, Comerota AJ. et al. Antithrom-botic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-e494S.
6 Park B, Messina L, Dargon P. et al. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest 2009; 136: 983-990.
7 de Miguel-Diez J, Jimenez-Garcia R, Jimenez D. et al. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. Eur Respir J 2014; 44: 942-950.
8 Fabia Valls MJ, van der Hulle T, den Exter PL. et al. Performance of a diagnostic algorithm based on a prediction rule, D-dimer and CT-scan for pulmonary embolism in patients with previous venous thromboembolism. A systematic review and meta-analysis. Thromb Haemost 2015; 113: 406-413.
9 Righini M, Le GG, Bounameaux H. Venous thromboembolism diagnosis: unresolved issues. Thromb Haemost 2015; 113: 1184-1192.
10 Mahan CE, Liu Y, Turpie AG. et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014; 112: 692-699.
11 Righini M, Van Es J, den Exter PL. et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. J Am Med Assoc 2014; 311: 1117-1124.
12 Piazza G, Hohlfelder B, Jaff MR. et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibri-nolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv 2015; 08: 1382-1392.
13 Kucher N, Boekstegers P, Muller OJ. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-486.
14 van Es N, Coppens M, Schulman S. et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
15 Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2015; 113: 231-246.
16 Majeed A, Goldhaber SZ, Kakkar A. et al. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost 2016; 115: 291-298.
17 Bookhart BK, Haskell L, Bamber L. et al. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ 2014; 17: 691-695.
18 Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011; 171: 831-837.
19 Tsai J, Grosse SD, Grant AM. et al. Trends in inhospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med 2012; 172: 960-961.
20 Raskob GE, Angchaisuksiri P, Blanco AN. et al. Thrombosis: A major contributor to global disease burden. Thromb Haemost 2014; 112: 843-852.
21 Wendelboe AM, McCumber M, Hylek EM. et al. Global public awareness of venous thromboem-bolism. J Thromb Haemost 2015; 13: 1365-1371.
22 Carrier M, Righini M, Wells PS. et al. Subsegmen-tal pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 08: 1716-1722.
23 Stein PD, Goodman LR, Hull RD. et al. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost 2012; 18: 20-26.
24 Hutchinson BD, Navin P, Marom EM. et al. Over-diagnosis of Pulmonary Embolism by Pulmonary CT Angiography. Am J Roentgenol 2015; 205: 271-277.
25 Dentali F, Ageno W, Pomero F. et al. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost 2016; 115: 399-405.